Compare MGM Resorts International (MGM) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MGM Resorts International vs Tango Therapeutics Inc. — how do they compare? MGM Resorts International trades at $28.73 (market cap $7.40B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: MGM Resorts International is the larger of the two by market cap, and MGM Resorts International pays a 0.03% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold MGM Resorts International for 92 Days and Tango Therapeutics Inc. for 0 Days on average.
| MGM | TNGX | |
|---|---|---|
Market Cap | $7.40B | $3.75B |
Volume | 3,687,296 | 9,619,106 |
Sector | Consumer Cyclical | Health |
52-Week High | $50.69 | $32.90 |
52-Week Low | $28.96 | $7.50 |
Typical Hold Time | 92 Days | 0 Days |
Enterprise Value | $34.70B | $2.77B |
Dividend Yield | 0.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MGM Resorts International (MGM) trades at $28.96, down 1.23% amid recent volatility following the collapse of Barry Diller's $48.30 per share acquisition offer. The stock shows bearish technical signals with oversold RSI readings, while fundamentals reveal mixed results with Q2 2026 EPS beating expectations but net margins declining to 2.4%. Recent news highlights ongoing M&A discussions, including potential MGM bids for People Inc., creating uncertainty around strategic direction.
Despite near-term headwinds, MGM maintains strong analyst support with 51% buy ratings and a $47.57 consensus target representing 64% upside. Key risks include execution on acquisition strategy, declining profitability margins, and high debt levels. The current valuation at 17.8x P/E appears reasonable if management can stabilize earnings and navigate the evolving casino landscape effectively.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
